Last reviewed · How we verify
Tiotropium & olodaterol
Tiotropium and olodaterol is a combination of a long-acting muscarinic antagonist and a long-acting beta-2 agonist that work together to relax and open airways in the lungs.
Tiotropium and olodaterol is a combination of a long-acting muscarinic antagonist and a long-acting beta-2 agonist that work together to relax and open airways in the lungs. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | Tiotropium & olodaterol |
|---|---|
| Also known as | Spiolto Respimat |
| Sponsor | University of Dundee |
| Drug class | Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) |
| Target | Muscarinic M3 receptor; beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Tiotropium blocks muscarinic receptors on airway smooth muscle, reducing bronchoconstriction, while olodaterol activates beta-2 adrenergic receptors to promote bronchodilation. Together, these complementary mechanisms provide sustained airway relaxation and improved airflow for patients with chronic obstructive pulmonary disease (COPD).
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
Key clinical trials
- A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects (PHASE1)
- ANTES B+ Clinical Trial (PHASE4)
- Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD (NA)
- A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler
- Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
- Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
- Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece
- Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tiotropium & olodaterol CI brief — competitive landscape report
- Tiotropium & olodaterol updates RSS · CI watch RSS
- University of Dundee portfolio CI